Long noncoding RNAs (lncRNAs), loosely defined as RNA molecules longer than 200 nucleotides that lack the general properties of protein-coding RNAs, have emerged as important regulators of gene expression at both the transcriptional and post-transcriptional levels.^[@R1]--[@R3]^ LncRNAs are often classified by their origins in the genome and their relationships to protein-coding regions.^[@R4]^ One subclass of lncRNA, natural antisense transcripts (NATs), is abundant in eukaryotic genomes.^[@R5]^ NATs share complementarity with protein-coding transcripts but are transcribed in the opposite orientation. We previously identified NATs from the tyrosine kinase containing immunoglobulin and epidermal growth factor homology 1 (*tie1*) loci in zebrafish (2 NATs), mice (1 NAT), and humans (3 NATs).^[@R6]^ None of those *tie1* antisense (*tie1AS*) transcripts have been shown to encode proteins, and all are \>200 nucleotides long. By current definition, they are therefore lncRNAs.

*Tie1* is an essential gene in development, and deletion of the murine *tie1* gene leads to local hemorrhage and edema, causing embryonic lethality.^[@R7],[@R8]^ TIE1 protein, encoded by the sense strand in the *tie1* locus, is a receptor tyrosine kinase expressed on the surfaces of endothelial cells and hematopoietic cells,^[@R9]^ and most of its function is context dependent.^[@R10]^ TIE1 protein is required for vessel integrity in the late phases of embryonic angiogenesis and for survival of endothelial cells in mature vessels.^[@R7],[@R8],[@R11],[@R12]^ Further, *Tie1* is differentially expressed across vascular beds.^[@R13]--[@R15]^ The critical role of *Tie1* and its nonuniform expression in different types of endothelia during embryogenesis and in adult tissues suggest tight regulation and control of its expression at the post-transcriptional and post-translational level. Although a large body of work describes post-translational regulation of *Tie1*, very little is known on the context-dependent post-transcriptional regulatory mechanisms for *tie1* mRNA. Here, we describe a molecular mechanism used by *tie1AS* and the RNA-binding protein embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1) to regulate *tie1* mRNA levels post-transcriptionally both spatially and temporally in the vascular bed of the developing zebrafish brain.

Materials and Methods
=====================

Data available on request from the authors.

Animal Research
---------------

All zebrafish (*Danio rerio*) studies were performed according to the Medical College of Wisconsin (MCW) animal protocol guidelines under protocol AUA320. The MCW Institutional Animal Care and Use Committee approved the studies conducted here. Transgenic lines used in this study included: *Tg(kdrl:eGFP), Tg(kdrl:eGFP)roy*^*a9*^*; mitfa*^*w2*^*, Tg(kdrl:NLS-EGFP)/Tg*(*−6.5kdrl:mCherry)*, and *Tg(kdrl:NLS-EGFP*). Additional details on the transgenic lines used are given in Major Resources Table in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1).

Wild-type or transgenic adult zebrafish males and females were crossed to obtain embryos. Only zebrafish embryos (1-cell stage to 48 hours post-fertilization \[hpf\]) were used in our experiments. To obtain freshly fertilized wild-type and transgenic zebrafish embryos, we crossed adult fish at a ratio of 1 male to 2 females, housing them overnight in off-system breeding tanks (1 L volume) at a density of ≤5 fish per tank. The fish were separated by a divider and were maintained in a crossing tank containing a breeding chamber and a lower collection chamber. Embryos were collected in the morning when the separator was removed. The embryos were placed in an incubator with an ambient temperature of 28.5°C. The embryo medium (E3) consisted of 5 mmol/L NaCl, 0.17 mmol/L KCl, 0.33 mmol/L CaCl~2~, and 0.33 mmol/L MgSO~4~.

For imaging studies, we anesthetized the embryos by incubating them in E3 medium containing a final concentration of 0.003% tricaine (3-amino benzoic acid ethyl ester; Sigma) at pH 7.

RNA Binding Ultraviolet Cross-Linking Assays
--------------------------------------------

Ultraviolet (UV) cross-linking assays were performed as described previously.^[@R16]^ In brief, probes were synthesized with the T7 bacteriophage RNA polymerase (Ambion) and α-\[P^32^\]-rUTP (ribonucleoside uridine triphosphate; Perkin Elmer, Boston, MA) from linearized, sequence-verified plasmids in which double-stranded oligos were ligated into the EcoR I and Hind III sites of pGEM3. 100 000 cpm of each probe was combined with 5 µL 2× binding buffer (1× binding buffer is 20 mmol/L HEPES \[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid\], 3 mmol/L MgCl~2~, 40 mmol/L KCl, and 1 mmol/L DTT \[dithiothreitol\], pH 7.6). Sequence-specific complexes were generated upon addition of 2 μL of total zebrafish 28 hpf extract (25--50 μg/μl) and 1-μL *E.coli* tRNA (5 mg/mL). The mixture was incubated for 30 minutes, UV cross-linked for 12 minutes at 254 nm, and RNA digested with 5-μg RNase I (Thermo Fisher; EN0602) for 10 minutes at 37°C. The samples were resolved on SDS-polyacrylamide gels and analyzed with a GE Storm 820 PhosphorImager.

RNA Pull-Down and Mass Spectrometry
-----------------------------------

Overlapping sense and antisense single-stranded DNA oligos were purchased from Eurofins MWG Operon LLC (Louisville, KY) and hybridized to obtain double-stranded DNA. All double-stranded DNA had the T7 promoter region at the 5′ end. The MaxiScript T7 (Ambion; AM1312) kit was used to transcribe RNA from double-stranded DNA in vitro. The RNA was biotinylated at its 3′ end, using a Pierce Desthiobiotinylation Kit (Thermo Scientific; 20163). Desthiobiotinylated RNA probes were incubated with streptavidin magnetic beads from a Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Scientific; 20164) as per kit protocol. After washes with Wash Buffer (Thermo Scientific; 20164), 200 µg of zebrafish total lysate (26--28 hpf) was added to the RNA-bound streptavidin magnetic beads, and the complex was incubated at 4°C with gentle agitation for 90 minutes. After three washes with Wash Buffer (Thermo Scientific; 20164), the RNA-bound proteins were eluted in SDS sample buffer and resolved by SDS-PAGE on 4% to 20% acrylamide gel (Bio-Rad, Hercules, CA). RNA-bound proteins were visualized by silver staining. Protein bands of interest were excised and sequenced by mass spectrometry (MS) at the Taplin Mass Spectrometry Facility (Harvard Medical School, Boston, MA). MS hits were analyzed for the number of unique and total peptides obtained and by determining the area under the curve. Each hit was digested in silico with trypsin, and the number of peptides obtained was compared with the number of peptides in the MS results. Vitellogenin, a yolk protein known to contaminate zebrafish embryo protein lysate,^[@R17]^ was excluded from the analysis.

RNA Extraction and Reverse Transcription-Quantitative Polymerase Chain Reaction
-------------------------------------------------------------------------------

Wild-type and transgenic zebrafish embryos were manually dechorionated with forceps. Whole embryo, head, and tail/trunk were manually dissected and homogenized in Trizol with a motorized pestle (Sigma Aldrich; Z359971). Heads were obtained by cutting behind the hindbrain ventricle, and tails/trunks were obtained by cutting at the start of the yolk sac extension with microscissors (World Precision Instruments). After Trizol treatment and DNase I digestion, RNA was purified with the help of RNeasy columns (Qiagen; 74034) as per the manufacturer's instructions. Three hundred nanograms to 500 ng of RNA was incubated with 50 mmol/L oligo(dT)20 primer (Invitrogen; 18418) and 10 mmol/L dNTPs (deoxynucleotide triphosphates), and heated to 65°C for 5 minutes. After being cooled on ice, the RNA was reverse transcribed to cDNA with Superscript III (Invitrogen; 18080044) as per the manufacturer's protocol. We performed quantitative real-time polymerase chain reaction (PCR) by mixing 1 μL cDNA with 10 μL 2× qPCR Buffer Mastermix iCycler (MidSci BEQPCR-IC) and 5 pmol of each forward and reverse *tie1*, *tie1AS*, or *gapdh* primer. Quantitative real-time PCR was also performed with *VE* (vascular endothelial)*-cadherin* and *p53* forward and reverse primers. The sequence of the primers is listed in Table II in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1). Fluorescence emitted during each cycle was monitored using the iQ5 Multicolor Real-Time PCR Detection System (BioRad, Hercules, CA). The absence of nonspecific products was determined by analyzing dissociation curves. End point PCR was performed by combining 1 μL cDNA with 5 pmol of each forward and reverse *tie1*, *tie1AS*, or *gapdh* primer, 10 μL 5× high-fidelity buffer, and 2 U of Phusion DNA polymerase (Thermo Scientific; F530L).

Western Blotting After RNA Pull-Down
------------------------------------

Western blotting was performed after the RNA pull-down to confirm the interaction between *tie1AS* and Elavl1. RNA pull-down was performed as mentioned above and resolved by SDS-PAGE on a 12% acrylamide gel (Bio-Rad, Hercules, CA). Proteins were electrophoretically transferred onto PVDF (polyvinylidene fluoride) membrane overnight at 12 V. After washes in 1× TBST (Tris-buffered saline tween20; 1× TBS with 1% Tween-20), the PVDF membrane was blocked in blocking solution (5% wt/vol BSA in 1× TBST) for 1 hour at room temperature. Anti-Elav antibody 1:500 (Invitrogen; A21271) was added and incubated overnight at 4°C. After washes in 1× TBST, the membrane was incubated for 1 hour with anti-mouse IgG (Cell Signaling; 7076S) in blocking solution (1:2000). The membrane was washed again in 1× TBST and developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher; 34078) on X-ray films (MidSci; EBNU2).

Whole Fish In Situ Hybridization, Fluorescence In Situ Hybridization, and Immunostaining
----------------------------------------------------------------------------------------

Whole fish in situ hybridization was performed as described previously.^[@R6]^ Fluorescence in situ hybridization and immunofluorescence were performed with an RNAscope kit from Advanced Cell Diagnostics, Inc, following the protocol described by Gross-Thebing et al.^[@R18]^ Fluorescence in situ hybridization probes to detect *tie1* mRNA and *tie1AS* lncRNA were designed by Advanced Cell Diagnostics, Inc. Probe details are mentioned in the Major Resource Table in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1). Anti-Elav antibody (Invitrogen; A21271) was used as the primary antibody to detect Elavl1, and Alexa Fluor 488 goat anti-mouse antibody (Invitrogen A11001) was used as the secondary. Control immunofluorescence staining was performed with anti-mouse IgG (Cell Signaling; 7076) as the primary antibody and Alexa Fluor 488 goat anti-mouse antibody (Invitrogen A11001) as the secondary.

*tie1AS*:Elavl1 Interaction Studies In Vivo
-------------------------------------------

The interaction between *tie1AS* lncRNA and Elavl1 in vivo was detected with a Magna RIP kit (Millipore 17--700) according to the manufacturer's protocol with the following modifications: zebrafish wild-type embryos (26--28 hpf) were dechorionated and washed in 1× PBS. Embryos were homogenized in 1× PBS with a motorized pestle (Sigma Aldrich; Z359971) and dissolved in lysis buffer from the Magna RIP kit. Anti-Elav antibody (Invitrogen; A21271), anti-tyrosine hydroxylase antibody (Pel Freeze; P-40101), or IgG from the kit was added to the kit's magnetic beads as per the manufacturer's protocol. After being washed with Wash Buffer (also from the kit), the antibody-bound magnetic beads were incubated with zebrafish lysate overnight at 4°C. Protein-bound RNAs were isolated according to the kit's protocol and reverse transcribed to cDNA. They were used in end point PCR and quantitative PCR, as described earlier.

CRISPRi Knockdown of *tie1AS*
-----------------------------

We knocked down *tie1AS* by following the CRISPRi (clustered regularly interspaced short palindromic repeats--mediated interference) method described in Long et al^[@R19]^ 2015. In brief, 3 guide RNAs (gRNAs) targeting the transcription start site of *tie1AS* (250 pg/embryo each) were coinjected with dCas9-KRAB (dead cas9 enzyme-kruppel-associated box domain) mRNA (catalytically inactive Cas9, 250 pg/embryo) into 1-cell stage zebrafish embryos: wild-type, *Tg(kdrl:eGFP)*, or *Tg(kdrl:NLS-EGFP)/Tg(-6.5kdrl:mCherry*). As a negative control, scrambled gRNAs (250 pg/embryo) were coinjected with dCas9-KRAB (250 pg/embryo). The dCas9-KRAB plasmids (pXT7-dCas9-KRAB) were generously donated by Dr Dong Liu of Peking University, China. The plasmids were linearized, and mRNA was synthesized in vitro for injections. gRNAs were generated as per Varshney et al^[@R20]^ 2015. RNA from at least 50 embryos or embryo heads was collected between 28 and 31 hpf and pooled for RT-qPCR analysis as described earlier. The average RT-qPCR value for *tie1AS* RNA (relative to *gapdh*) from 3 biological replicates was compared between the control knockdown group and the *tie1AS* knockdown group to determine the efficacy of CRISPRi-mediated knockdown of *tie1AS*. *tie1* mRNA levels in the control CRIPSRi group and the *tie1AS* CRISPRi group were determined by the method used for *tie1AS* lncRNA. The difference in *tie1AS* levels between the control CRISPRi group and the *tie1AS* CRISPRi group was analyzed for statistical significance as described in Imaging, Quantification, and Statistical Analysis.

CRISPRi gRNA Sequences
----------------------

Sequences of the T7 promoter gRNAs cassettes used in this study were as follows, with the T7 promoter italicized:

1.  *TTAATACGACTC ACTATA*GA TGAGTTGTTTTC TT CAG TGT TT TAGAGCT AGAAATAGCAAGTTAAAA TA AGGC TAGTCCGTTA TCAACTTGAA AAAGTGGCACCGAGTCGGTGCTTTT

2.  *TTAATAC GACT CACTATA*G AG G TTGAC TTG CGTTTTCTGT TTTAG A GC TAGAAATAGCAAG TTAAAA TAAGGCTA GTCCGTTA TCAACTTGAA AAAGTGGCA CCGAGTCGGTGCTTTT

3.  *TTAATACG ACTCA CTATA* GACAAAAG CTCAA TTAGCATGTT TTAGAGC TAGAAATAGCAA GTTAAAA TAAGGCTA GTCCGT TA TCAAC TTGAAAA AGTGGCACCGAG TCGGTGCTTTT

The scrambled gRNA used in the study had the following sequence, with the T7 promoter italicized:

*TT AAT ACGA CTCACTATA* GTTTTAG AGCTA GAAAT AGCA AGTTAAA ATAA GGCTA GT CCGTTATC AACTTGAAA AAGTGGCACCGA GTCG GTGCTTTT

Morpholino Studies
------------------

Gene Tools Inc designed the morpholinos that blocked the Elavl1-binding site (*tie1AS*-Elavl-bMOs) and the control morpholino oligonucleotides (cMOs). MO injections were performed as described previously.^[@R6]^ Photo-cleavable morpholinos obtained from Gene Tools Inc were incubated with cMO or *tie1AS*:Elavl-bMO1 at a ratio of 1.2:1 to form a photo-cleavable MO:MO complex (pMO complexes) that cages MOs to render them inactive. Two nanograms of pMO complexes was injected into 1-cell zebrafish embryos, which were developed to 14 to 16 somite (som) stages in petri dishes at 28.5°C in the dark before being exposed to 365 nm UV light in a light box for 8 minutes. After the MO was photo-activated, the embryos were returned to the 28.5°C incubator. Between 28 and 31 hpf, their phenotypes were analyzed. Then their RNA was extracted, processed, and quantified by RT-qPCR, as described earlier. RT-qPCR values for *tie1* mRNA and *tie1AS* RNA (relative to *gapdh*) were obtained from at least 3 biological replicates for embryos injected with cMO/control pMO or *tie1AS*-Elavl-bMOs/*tie1AS*-Elavl-pMO. The average RT-qPCR values, along with SDs, were plotted in Figures [3](#F3){ref-type="fig"} and [5](#F5){ref-type="fig"} and Figures IX, XI, XVI, XVIII, and XIX in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1). We determined the significance of the difference between the RT-qPCR values of the control group versus the experimental groups (modulation of the Elavl1-*tie1AS* interaction or *tieAS* knockdown) as described below.

Imaging, Quantification, and Statistical Analysis
-------------------------------------------------

Details related to this section are available in the Supplemental Materials section in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1).

Drug Treatment
--------------

SB-505124, a selective inhibitor of TGF (transforming growth factor)-βR, was purchased from Millipore Sigma (catalogue number S4696) and dissolved in dimethyl sulfoxide (DMSO) as per the manufacturer's instructions. One-cell-stage *Tg(kdrl:eGFP*) embryos were injected with cMO or *tie1AS*-Elavl-bMO^comb^ and allowed to grow in the dark at 28.5°C. Between 18 and 20 somite stages, we treated 20 to 25 embryos per petri dish (60×15 mm) with either 100 μm DMSO or 100 μm SB-505124 (diluted in E3 solution). Embryos were grown until 28 to 31 hpf, dechorionated, washed 3× in E3 solution and imaged (phase contrast, fluorescence, and confocal) or processed for RNA extraction as described earlier.

Results
=======

Elavl1 Protein Interacts With *tie1AS*
--------------------------------------

Previously, we demonstrated that an 804-nucleotide zebrafish *tie1AS* lncRNA forms a duplex with *tie1* mRNA in the cytoplasm and that overexpression of the *tie1AS* lncRNA leads to specific degradation of *tie1* mRNA.^[@R6]^ *tie1AS* lncRNA is complementary in sequence to *tie1* mRNA apart from a 148 nucleotide-long region in the 5′ end, referred to as a unique sequence (Figure [1](#F1){ref-type="fig"}A). We hypothesized that *tie1AS* uses the unique sequences to interact with protein(s) involved in the regulation of *tie1* mRNA (resembling the way that mouse ubiquitin carboxyl-terminal hydrolase L1 \[*Uchl1*\] antisense lncRNA regulates *Uchl1* mRNA^[@R21]^). To test our hypothesis, we performed RNA affinity chromatography (RNA pull-down assay) to detect any RNA-binding proteins that interact with the unique sequences in *tie1AS* lncRNA. We divided the 148 nucleotide-long unique sequence into 3 overlapping fragments: *tie1AS*~(1--70)~, *tie1AS*~(45--105)~, and *tie1AS*~(88--151)~ (Figure [1](#F1){ref-type="fig"}A) and generated biotinylated RNA probes. We then incubated those probes with zebrafish embryo lysate (26 to 28 hpf). This time point was chosen because we previously observed that *tie1AS* and *tie1* mRNA levels peak around 24 hpf. Zebrafish proteins interacting with biotinylated RNA probes were pulled down with streptavidin magnetic beads, separated on SDS-PAGE gel, and visualized with silver stain (Figure [1](#F1){ref-type="fig"}B). Interestingly, only *tie1AS*~(88--151)~ showed a specific complex---at 37 kDa (Figure [1](#F1){ref-type="fig"}B, lane labeled *tie1AS*~(88--151)~, arrow)---though all 3 probes and scrambled RNA (our negative control) produced nonspecific complexes at ≈40 kDa (Figure [1](#F1){ref-type="fig"}B, asterisk). We excised the *tie1AS*~(88--151)~--protein complex and analyzed its proteins through MS (Table I in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Spectral counts and a comparison of average precursor intensities identified Embryonic lethal abnormal vision *Drosophila*-like 1 (Elavl1) as the most abundant protein in the complex. This method of quantifying the relative abundance of proteins in MS samples was previously used in Cullinane et al^[@R22]^ in 2015. We focused on the interaction between Elavl1 and *tie1* because both have been implicated in angiogenesis.^[@R23],[@R24]^

![Identification of embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1) interaction with unique sequences in *tyrosine kinase containing immunoglobulin and epidermal growth factor homology 1 antisense* (*tie1AS*) long noncoding RNA (lncRNA). **A**, Diagram of the convergent *tie1* mRNA and *tie1AS* lncRNA hybrid. *tie1AS* lncRNA sequences noncomplementary to *tie1* mRNA are shown as unique sequences. The unique sequences in *tie1AS* were subdivided into 3 probes with overlapping regions: *tie1AS*~(1--70)~ \[purple\], *tie1AS*~(45--105)~ \[cyan\], and *tie1AS*~(88--151)~ \[red\]. These probes were used in RNA pull-down assays and ultraviolet (UV) cross-linking assays. Elavl1-binding sites in *tie1AS* are underlined in red. **B**, The 3 RNA probes described in **A** and a scrambled RNA were transcribed in vitro, biotinylated at the 3′ end, and used in RNA pull-down assays as described in Methods in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1). From **left** to **right**, scrambled RNA (negative control), *tie1AS*~(1--70)~, *tie1AS*~(45--105)~, and *tie1AS*~(88--151)~. The asterisk indicates the nonspecific ribonucleoprotein complex. The black arrow points to the *tie1 AS*-specific RNA-protein complex, which was excised and analyzed by mass spectrometry. **C**, Biotinylated RNAs (**B**) were incubated with zebrafish lysate (26--28 hours post-fertilization \[hpf\]), resolved by SDS-PAGE, and blotted onto a PVDF membrane. The membrane was probed with anti-Elav antibody (primary) and anti-mouse antibody (secondary), and developed by chemiluminescence. **D**, Zebrafish 26 to 28 hpf lysate was incubated with protein A-bound anti-Elav antibody, protein A-bound Tyrosine Hydroxylase (TH) antibody, or IgG, and immobilized on magnetic beads. The beads were isolated and washed, and the RNA was extracted. After reverse transcription, the cDNA obtained was used in quantitative PCR. The *x* axis shows the antibodies used in immunoprecipitation. The *y* axis shows the percentages of *tie1AS* lncRNA (dark gray) or *tie1* mRNA (light gray) obtained relative to the input. **E**, UV cross-linking of RNA and zebrafish lysate. RNA labeled with \[α\]P^32^-UTP was incubated with zebrafish lysate (26--28 hpf) and cross-linked with UV for 12 minutes. After digestion with RNase I, the complexes were boiled in 2× SDS sample buffer and resolved by SDS-PAGE. The gel was visualized using a phosphorimager. RNA probes from **left** to **right**, *tie1AS*~(1--70)~, *tie1AS*~(40--105)~, wild-type *tie1AS*~(88--151)~ in 2 successive lanes, and mutated *tie1AS*~(88--151),~ *tie1AS*~mut,~UAAACUAACAGCAA*GCUGCCUGGUC*AGAGCAGAACAGAUGACUUUCAGUAAGGAUAGGAUAAUGCAUCGUUU (mutated sequences are underlined). The black arrow indicates that mutations within the adenosine uridine-rich element prevent the formation of the ribonucleoprotein complex.](atv-38-1562-g001){#F1}

We repeated the RNA pull-down assay and performed Western blotting with an anti-Elav antibody, which confirmed that Elavl1 binds to *tie1AS*~(88--151)~ (Figure [1](#F1){ref-type="fig"}C, lane 4) but not to *tie1AS*~(1--70)~, *tie1AS*~(45--105)~, or the negative control (Figure [1](#F1){ref-type="fig"}C, lanes 1--3). The anti-Elav antibody was raised against the human Elav orthologues HuB (human antigen B), HuC, and HuD and was previously used to detect zebrafish Elavl1^[@R25]^ and Elavl3.^[@R26]^ Indeed, the antibody cross-reacts with all 4 members of the zebrafish Elav family of proteins: Elavl1 (HuR, HuA), Elavl2 (HuB), Elavl3 (HuC), and Elavl4 (HuD; Figure I in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), which differ in size: 37 kDa, 42 kDa, 39 kDa, and 52 kDa, respectively. We therefore concluded that the 37 kDa protein that interacts with *tie1AS* ~(88--151)~ is Elavl1. However, we observed 2 bands of almost similar size in the Western blot (Figure [1](#F1){ref-type="fig"}C), and 2 isoforms of Elavl1 (Elavl1a and Elavl1b) have been reported in zebrafish, with Elavl1a accounting for 90% of Elavl1 proteins.^[@R27]^ To confirm that *tie1AS* lncRNA interacts with Elavl1 in vivo, we used the anti-Elav antibody to immunoprecipitate Elav-like proteins from 26 to 28 hpf zebrafish lysates. Then, we reverse transcribed the RNA and used quantitative PCR for *tie1AS* or *tie1* mRNA. Indeed, we found that *tie1AS---*but not *tie1---*coprecipitated with Elav-like proteins (Figure [1](#F1){ref-type="fig"}D). The negative control immunoprecipitated with anti-IgG, and anti-tyrosine hydroxylase antibodies failed to pull-down *tie1AS* (Figure [1](#F1){ref-type="fig"}D). Also, abundant RNAs, such as *gapdh*, did not coprecipitate with Elavl1 nonspecifically (Figure II in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Thus, our in vitro and in vivo results together show that *tie1AS* lncRNA and Elavl1 form a complex together.

To narrow down the Elavl1-binding site within *tie1AS*, we performed UV cross-linking assays by incubating body-labeled RNA probes \[*tie1AS*~(1--70)~, *tie1AS*~(45--105)~, and *tie1AS*~(88--151)~\] with zebrafish total lysate. We resolved the RNA--protein complexes on SDS-PAGE gel and visualized them by autoradiography. As in the RNA pull-down assays described above, only *tie1AS*~(88--151)~ (Figure [1](#F1){ref-type="fig"}E, lane 3, and lane 4) and not *tie1AS*~(1--70)~ or *tie1AS*~(45--105)~ (Figure [1](#F1){ref-type="fig"}E, lanes 1--2) produced 2 ribonucleoprotein complexes at ≈37 kDa. Because Elav proteins are known to bind adenosine uridine (AU)-rich elements within RNA^[@R28]^---and given that *tie1AS* lncRNA harbors an AU-rich element, UUAAUUUUAU, between nucleotides 105 and 115---we investigated whether this element is required for binding Elavl1. Mutation of the AU-rich element within *tie1AS*~(88--151)~ (5′UUAAUUUUAU3′ to GCUGCCUGGC3′) prevented the specific ribonucleoprotein complex from forming at 37 kDa (Figure [1](#F1){ref-type="fig"}E, compare lane 4 to lane 5, arrow). Thus, a 10 nucleotide element, 5′UUAAUUUUAU3′, within *tie1AS*~(88--151)~ is necessary for *tie1AS* to interact with Elavl1.

Next, we investigated the spatial expression of *tie1* mRNA, *tie1AS* lncRNA, and Elavl-like proteins in 26 to 28 hpf zebrafish embryos. We used double fluorescence in situ hybridization to detect *tie1* mRNA (Figure [2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}D; Figures III, V, VI, and VII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1); Movie I in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) and *tie1AS* lncRNA (Figure [2](#F2){ref-type="fig"}B and [2](#F2){ref-type="fig"}D; Figures III, IV, VI, and VII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1); Movie M1 in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) followed by immunofluorescence staining for Elav-like proteins (Figure [2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D; Figures III, IV, VI, and VII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1); Movie I in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) in 26 to 28 hpf embryos. Our results show that both *tie1AS* and Elav-like proteins have broad regions of expression in the head (Figure [2](#F2){ref-type="fig"}; Figures IV and VI in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) but not in the tail or trunk (Figure III in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). In the 26 to 28 hpf head, we observed close apposition of *tie1* mRNA expression (Figure [2](#F2){ref-type="fig"}A; Figure V in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) with head vessels, and that expression region was sharply demarcated. In contrast, *tie1AS* lncRNA (Figure [2](#F2){ref-type="fig"}B) was expressed almost exclusively in regions of head where *tie1* mRNA was absent. In the merged image (Figure [2](#F2){ref-type="fig"}D), note the regions of exclusivity for *tie1* mRNA and *tie1AS* lncRNA along carotid arteries and primordial midbrain channels (PMBCs). Expression of Elav-like proteins (Figure [2](#F2){ref-type="fig"}C), was abundant in the forebrain (f), hindbrain (hb), and developing eyes (e). To investigate any overlap in expression, especially between *tie1AS* and Elav-like proteins, we performed a detailed analysis (Methods in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) across all the z-stack images that contributed to the merged image in Figure [2](#F2){ref-type="fig"}D, using the colocalization module of LSM510 software (Figures IV and VI in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)).

![Spatial expression of *tyrosine kinase containing immunoglobulin and epidermal growth factor homology 1* (*tie1*) mRNA, *tie1 antisense* (*tie1AS*) long noncoding RNA (lncRNA), and embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1) protein in the head of 26 to 28 hours post-fertilization (hpf) zebrafish embryo. **A--D**, Following double fluorescence in situ hybridization (RNAscope) to detect *tie1* mRNA and *tie1AS* lncRNA expression, we used immunofluorescence to detect Elav-like protein expression in the same embryo. Representative (6/6) confocal photomicrographs of zebrafish embryo head (lateral) between 26 and 28 hpf captured with a 20× objective lens and processed as z-projections show *tie1* mRNA expression in magenta (**A**), *tie1AS* lncRNA expression in yellow (**B**), and Elav-like protein expression in cyan (**C**). **A**--**C**, Merged in **D**. **E**, Diagram of 28 hpf zebrafish embryo. Inset: Blow-up of head vasculature. Veins are shown in blue, arteries in red. Vessels indicated are cranial division of the internal carotid artery (CrDI), primordial midbrain channel (PMBC), middle cerebral vein (MCeV), primordial hind-brain channel (PHBC), anterior cerebral vein (ACeV), lateral dorsal aortae (LDA), aortic arch 1 (AA1), primitive internal carotid arteries (PICA), caudal division of the internal carotid artery (CaDI), and primitive mesencephalic artery (PMsA). e indicates eye; f, forebrain; and hb, hindbrain.](atv-38-1562-g002){#F2}

This analysis was necessary because the signal associated with Elav-like proteins was overwhelmingly strong across most 1 micron z-stack sections, whereas the signal for *tie1AS* was very strong in some z-stack sections at submicron level. The imaging analysis showed strong overlap between the expression of *tie1AS* lncRNA and Elav-like proteins in the forebrain, hindbrain, and eye (Figures IV and VIC in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). When *tie1* mRNA expression was included in this analysis, overlap between the 3 molecules was limited to only a few cells in the eye (Figure VI in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). We concluded from this spatial analysis that there is considerable overlap between the expression of *tie1AS* and Elavl1 at 26 to 28 hpf but that those 2 molecules overlap with *tie1* mRNA only in a small number of cells.

Functional Analysis of *tie1AS*:Elavl1
--------------------------------------

We used 3 distinct approaches to explore the functional relevance of the interaction between *tie1AS* and Elavl1 (Figure VIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)): (1) morpholino antisense oligonucleotides^[@R29]^(MOs), (2) photoactivatable caged MOs (pMOs),^[@R30]^ and (3) CRISPR/Cas9 technology-based transcriptional repression/knockdown^[@R31]^ of *tie1AS* lncRNA (CRISPRi).

Using 2 different MOs---*tie1AS*-Elavl-bMO1 and *tie1AS*-Elavl-bMO2---we blocked Elavl1-binding sites in *tie1AS* (Table II and Figure VIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). When the 2 MOs were injected separately (1 ng each), levels of *tie1* mRNA and *tie1AS* lncRNA were not significantly different from those in embryos injected with cMO (Figure IX in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). However, when we injected 2 ng of *tie1AS*-Elavl-bMO1 or 2 ng of *tie1AS*-Elavl-bMO2 separately or coinjected the 2 MOs (1 ng each; *tie1AS*-Elavl-bMO^comb^), we observed a 2-fold increase in *tie1* mRNA levels in whole embryo (Figure [3](#F3){ref-type="fig"}A) and a 2-fold increase in the head (Figure [3](#F3){ref-type="fig"}B). In contrast, *tie1AS* levels were 0.4-fold lower in the head (Figure [3](#F3){ref-type="fig"}E) at 28 to 31 hpf than when we injected the cMOs. We validated the ability of *tie1AS*-Elavl-bMO^comb^ to disrupt the interaction between *tie1AS* and Elavl1 through an in vitro ribonucleoprotein complex formation assay (Figure X in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). We also did not observe changes in levels of *p53* mRNA, a gene known to be nonspecifically induced by MO injection,^[@R32]^ or in levels of *VE-cadherin* mRNA, an important regulator of angiogenesis (Figure XI in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). When we compared the embryos injected with cMO (Figure [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B) with those injected with *tie1AS*-Elavl-bMO^comb^, we saw a 0.5-fold decrease in eye size (Figure [4](#F4){ref-type="fig"}C, red arrow and E), a 0.4-fold reduction in ventricular space (Figure [4](#F4){ref-type="fig"}C, red asterisk and V), and a 2-fold increase (dilation) in the size of PMBCs (Figure [4](#F4){ref-type="fig"}D, white outline and P). The defects coincided with changes in *tie1* and *tie1AS* lncRNA RNA levels in the head (Figure [3](#F3){ref-type="fig"}). By performing chromogenic in situ hybridization on embryos injected with 28 hpf *tie1AS*-Elavl1-bMO^comb^, we found a strong correlation between the change in the spatial expression of *tie1* mRNA in the head and abnormalities in the head vasculature (compare Figure [4](#F4){ref-type="fig"}M with Figure [4](#F4){ref-type="fig"}N, white arrows; also compare Figure XIIA and XIIB in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). We subclassified those embryos into 4 phenotypes: (1) normal/unaffected (38.3%, n=300), (2) mild (32%, n=300), (3) moderate (21%, n=300), and (4) severe (11.7%, n=300; Figure XIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). (Descriptions of each phenotype are given in Figure XIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1).)

![Analysis of *tyrosine kinase containing immunoglobulin and epidermal growth factor homology 1* (*tie1*) mRNA and *tie1 antisense* (*tie1AS*) RNA levels in zebrafish embryos injected with *tie1AS*-Elavl-bMO^comb^. One-cell wild-type or *Tg(Kdrl:eGFP*) zebrafish embryos were injected with control morpholino oligonucleotides (cMOs) or morpholinos targeting the embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1)--binding sites in *tie1AS* (*tie1AS*-Elavl-bMO^comb^). The embryos were grown at 28.5°C, and at least 50 were collected at time points shown on the *x* axis. RNA was extracted from whole embryos (**A** and **D**), embryo heads (**B** and **E**), or trunk/tail (**C** and **F**) and used in RT-qPCR. Levels of *tie1* and *tie1AS* RNA relative to *gapdh* mRNA expression are shown for embryos injected with cMO (blue open squares) or *tie1AS*-Elavl-bMO^comb^ (red open squares). Error bars represent SDs. For each specified time point, the difference was analyzed for statistical significance. The asterisk denotes adj *P*\<0.05 after multiple testing corrections. In **A** and **D**, n=≈50 embryos were analyzed per time point, with a total of 3 biological replicates. In **B**, **C**, **E**, and **F**, n=50 to 60 embryo heads or trunks/tails were analyzed per time point, with a total of 3 biological replicates.](atv-38-1562-g003){#F3}

![Phenotypic evaluation of CRISPRi (clustered regularly interspaced short palindromic repeats--mediated interference) embryos and embryos injected with morpholino (MO) or photoactivatable morpholino (pMO). One-cell stage *Tg(kdrl:eGFP*) zebrafish embryos that expressed eGFP(enhanced green fluorescent protein) in the blood vasculature were injected with control morpholinos (cMOs) or morpholinos targeting the embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1)--binding sites in *tyrosine kinase containing immunoglobulin and epidermal growth factor homology 1 antisense* (*tie1AS*; *tie1AS*-Elavl-bMO^comb^). The embryos were grown at 28.5°C and analyzed between 28 and 31 hours post-fertilization (hpf) for phenotype (**A**--**D**). **A**, A lateral phase-contrast image of a 28 hpf embryo injected with cMO. **B**, The corresponding fluorescence image. **C**, A lateral phase-contrast image of a 28 hpf embryo injected with *tie1AS*-Elavl-bMO^comb^. **D**, The corresponding fluorescence image. **A**, **B**, Representative of 102 of the 114 embryos observed. **C**, **D**, Representative of 159 of 300 embryos. Two nanograms of photoactivatable control morpholinos (control pMO) or photoactivatable caged morpholinos targeting Elavl1-binding sites in *tie1AS* (*tie1AS*-Elavl-pMO) were injected into 1-cell *Tg(kdrl:eGFP*) embryos, allowed to develop in the dark at 28.5°C to the 14 to 16 somite stage and exposed to 365 nm ultraviolet to activate the pMOs. The embryos were imaged between 28 and 31 hpf. **E**, A representative (170/200) phase-contrast image of an activated control pMO embryo and (**F**) and its corresponding fluorescence image. **G**, Representative (123/300) phase-contrast image of an activated *tie1AS*-Elavl-pMO embryo and (**H**) its corresponding fluorescence image. *Tg(kdrl:eGFP*) embryos were injected at the 1-cell stage with 250 pg of scrambled guide RNAs (gRNAs) along with 250 pg of dCas9-KRAB (dead cas9 enzyme-kruppel-associated box domain; scgRNA+dCas9) or 250 pg of guide RNAs targeting *tie1AS* transcription start site (TSS), along with dCas9-KRAB (*tie1AS* gRNAs+dCas9). They were allowed to develop at 28.5°C, and were imaged between 28 and 31 hpf. **I**, A representative (88/100) phase-contrast image of scgRNA+dCas9 and (**J**) its corresponding fluorescence image. **K**, A representative (90/200) phase-contrast image of a *tie1AS* gRNAs+dCas9 embryo and (**L**) its corresponding fluorescence image. **M**, Embryos injected with control morpholinos (cMO) or (**N**) *tie1AS*-Elavl-bMO^comb^ were fixed between 28 and 31 hpf, and chromogenic in situ hybridization was used to detect the expression of *tie1* mRNA. Purple staining in **M** and **N** shows *tie1* mRNA expression. **M**, Representative of 18 of 20 embryos analyzed, and **N** is representative of 10 of 25 embryos analyzed. White dotted lines in **B**, **D**, **F**, **H**, **J**, and **L** outline primordial midbrain channels (PMBCs; denoted by P). Red arrows next to E denote smaller eyes, and red asterisks under the V in **C**, **G**, and **K** denote reduced ventricular space. White arrows in **M** and **N** indicate *tie1* mRNA expression along PMBC. Outlines of eyes, ventricular space, and PMBCs were traced in lateral images (phase-contrast or fluorescence) with Axiovision 4.8.2, and areas within the outlines were deduced with the Measure tool from Axiovision 4.8.2. We then plotted the average areas of eyes (**O**), ventricular spaces (**P**), and PMBCs (**Q**) for the embryos injected with cMO (blue bars), *tie1AS*-Elavl-bMO^comb^ (red bars), control pMO (light gray bars), or *tie1AS*-Elavl-pMO (dark gray bars) and for the control clustered regularly interspaced short palindromic repeats interference (CRISPRi; green bars) and *tie1AS* CRISPRi embryos (yellow bars). Error bars represent SDs (n=6). \*Adj *P*\<0.05, \*\*Adj *P*\<0.01, and \*\*\*Adj *P*\<0.001 (*P* adjusted after multiple testing corrections). The horizontal lines under the asterisks denote the groups compared.](atv-38-1562-g004){#F4}

To understand how *tie1* mRNA is regulated by *tie1AS*--Elav-like protein in space and time, we determined whether the 2 molecules colocalize in the head at 48 hpf (Figure XIV in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), a time point at which disrupting the interaction between *tie1AS* and Elavl1 has no effect on *tie1* mRNA levels (Figure [3](#F3){ref-type="fig"}C). Our data show that, at 48 hpf, Elav-like proteins are expressed in a limited number of cells in the eye and the hind brain, where *tie1AS* and *tie1* mRNA are not expressed (Figure XIIIA in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Thus, in contrast to the 26 to 28 hpf embryonic stages (Figure [2](#F2){ref-type="fig"}), there was no overlap between the spatial expression of *tie1AS* and Elav-like proteins in the 48 hpf head. However, the expression patterns of Elav-like proteins in the trunk and tail are similar at 26 to 28 hpf and 48 hpf (Figures III versus XIIIB in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). From this constitutively active MO approach, we conclude that interaction between *tie1AS* and Elavl1 around 28 hpf is indeed required to regulate *tie1* mRNA levels in the head of the zebrafish embryo.

To further investigate temporal aspects of *tie1AS*-mediated regulation of *tie1* mRNA, we used a pMO. Photo-cleavable MOs have been shown to be nontoxic to embryonic zebrafish,^[@R33]^ as has exposure to UV for \>10 minutes post-gastrulation (5 hpf).^[@R33]^ The photo-cleavable MO (pMO1) complementary to the *tie1AS*-Elavl-bMO1 we used previously caged *tie1AS*-Elavl-bMO1 (Figure VIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). On exposure to UV light, the photo-cleavable MO in the *tie1AS*-Elavl-bMO1:pMO1 complex (*tie1AS*-Elavl-pMO) was cleaved, facilitating the activation of *tie1AS*-Elavl-bMO1 and its binding to its target (additional details in Methods and Figure VIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). This strategy allowed us to explore the temporal activation of MOs. We injected control pMO or *tie1AS*-Elavl-bMO1:pMO mix (1:1.2) (*tie1AS*-Elavl-pMO) into 1-cell zebrafish embryos that were then incubated in the dark at 28.5°C. Between the 14 and 16 somite stages, the embryos were exposed to 365 nm UV light for 8 minutes to activate the MO. They were then developed at 28.5°C and analyzed for RNA levels and morphological defects between 28 and 31 hpf. Compared with the embryos activated with control pMO (Figure [4](#F4){ref-type="fig"}E and [4](#F4){ref-type="fig"}F; Figure XVE and XVF in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), the embryos activated by *tie1AS*-Elavl-pMO (Figure [4](#F4){ref-type="fig"}G and [4](#F4){ref-type="fig"}H; Figure XVG and XVH in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) showed a 0.3-fold reduction in eye size (Figure [4](#F4){ref-type="fig"}G, red arrow and E), a 0.3-fold reduction in ventricular space (Figure [4](#F4){ref-type="fig"}G, red asterisk and V), a 1.6-fold increase in the size of PMBCs (Figure [4](#F4){ref-type="fig"}H, white outline and P), and an increase in *tie1* mRNA levels in the head (Figure XVI in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Dilated PMBCs, reduced ventricular space, and smaller eyes were noticed in ≈40% of the embryos activated with *tie1AS*-Elavl-pMO (n=300). Thus, our pMO approach confirmed the constitutive MO results and also showed that Elavl1-bound *tie1AS* downregulates *tie1* mRNA levels in the head post-segmentation between 28 and 31 hpf.

Using a third independent approach, we downregulated *tie1AS* transcription with CRISPR interference (CRISPRi; Figure VIII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), following a protocol described in Long et al^[@R19]^ 2015. We preferred CRISPRi to the more conventional CRISPR because of the proximity of the Elavl1-binding sites to the *tie1*-coding sequences and because of the scarcity of available canonical protospacer adjacent motif sites (NGG) near Elavl1-binding sites in *tie1AS*. We injected 3 gRNAs that target the transcription start site of *tie1AS* into zebrafish embryos together with a catalytically inactive form of Cas9 fused to the repressive Krüppel-associated box domain (dCas9-KRAB). As a control, we coinjected scrambled gRNAs with dCas9-KRAB. The embryos were developed until 28 to 31 hpf at 28.5°C and analyzed for *tie1AS* levels. Compared with the control (scrambled gRNA+dCas9-KRAB), there was a 5-fold decrease in *tie1AS* levels in whole embryos and a 2.3-fold decrease in the heads of embryos coinjected with the gRNAs that targeted the transcription start site of *tie1AS* and dCas9-KRAB (Figure XVIIIA and XVIIIB in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). As in the case of the MO and pMO-based approaches, CRISPRi-mediated knockdown of *tie1AS* caused an increase (≈2-fold) in *tie1* mRNA levels (Figure XVIIIB and XVIIID in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), a 0.4-fold reduction in eye size (Figure [4](#F4){ref-type="fig"}K, red arrow and E), a 0.3-fold reduction in ventricular space (Figure [4](#F4){ref-type="fig"}K, red asterisk and V), and dilated PMBCs (Figure [4](#F4){ref-type="fig"}L, white outline and P) compared with the control embryos (Figure [4](#F4){ref-type="fig"}I and [4](#F4){ref-type="fig"}J; Figure XVIIA and XVIIB in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). The defects were apparent in ≈50% of the *tie1AS* knockdown embryos (n=200). Thus, with all 3 approaches, we noticed improper brain vessel patterning and morphological defects (smaller eyes and reduced ventricular space) that coincided with elevated *tie1* mRNA levels in the head.

We used the MO approach to further analyze the correlation between increased *tie1* mRNA levels and changes in eye size, ventricular space, and PMBCs. We injected 1-cell transgenic zebrafish embryos with cMO or *tie1AS*-Elavl-bMO^comb^, developed the embryos at 28.5°C, and treated them with either 100 µm DMSO or 100 µm SB-505124 between somite stages 18 and 20. SB-505124 is a commercially available selective inhibitor of TGFβ type I receptors that was previously shown to reduce *tie1* mRNA expression in embryonic zebrafish.^[@R34]^ Using this reagent, we determined the phenotypic effects of decreasing *tie1* mRNA in embryos injected with *tie1AS*-Elavl1-bMO^comb^. We did not observe any statistically significant difference in eye size, ventricular space, or PMBCs between the cMO embryos treated with DMSO or SB-505124 (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B versus [5](#F5){ref-type="fig"}C and [5](#F5){ref-type="fig"}D, and blue bars versus light gray bars in Figure [5](#F5){ref-type="fig"}I through [5](#F5){ref-type="fig"}K). When we compared the cMO+DMSO group with the *tie1AS*-Elavl-bMO^comb^+DMSO group, however, we observed a statistically significant decrease in eye size (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B versus [5](#F5){ref-type="fig"}E and [5](#F5){ref-type="fig"}F, and [5](#F5){ref-type="fig"}I, dark blue versus red bars) and ventricular space (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B versus [5](#F5){ref-type="fig"}E and [5](#F5){ref-type="fig"}F, and [5](#F5){ref-type="fig"}J, dark blue versus red bars) and an increase in PMBCs (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B versus [5](#F5){ref-type="fig"}E and [5](#F5){ref-type="fig"}F, and [5](#F5){ref-type="fig"}K, dark blue versus red bars), which is consistent with our previous findings (Figure [4](#F4){ref-type="fig"}). Moreover, when we compared the *tie1AS*-Elavl-bMO^comb^+DMSO embryos with the *tie1AS*-Elavl-bMO^comb^+SB-505124 embryos (Figure [5](#F5){ref-type="fig"}E and [5](#F5){ref-type="fig"}F versus [5](#F5){ref-type="fig"}G and [5](#F5){ref-type="fig"}H; red bars versus dark grey bars in Figure [5](#F5){ref-type="fig"}I through [5](#F5){ref-type="fig"}K), we saw statistically significant increases in eye size (0.5-fold) and ventricular space and a decrease (1.8-fold) in PMBCs. Furthermore, the cMO+SB-505124 and *tie1AS*-Elavl-bMO^comb^+SB-505124 embryos (Figure [5](#F5){ref-type="fig"}C and [5](#F5){ref-type="fig"}D versus [5](#F5){ref-type="fig"}G and [5](#F5){ref-type="fig"}H and [5](#F5){ref-type="fig"}I through [5](#F5){ref-type="fig"}K, compare light gray bars to dark gray bars) were similar in eye size, ventricular space, and PMBCs, resembling the cMO+DMSO group. These results collectively imply that suppressing *tie1* mRNA levels in embryos injected with *tie1AS*-Elavl-bMO^comb^ rescues the 3 phenotypes.

![Phenotypic evaluation and analysis of *tyrosine kinase containing immunoglobulin and epidermal growth factor homology* 1 (*tie1*) mRNA levels in embryos treated with morpholino or dimethyl sulfoxide (DMSO)/SB-505124. One-cell *Tg(kdrl:eGFP*) zebrafish embryos were injected with control morpholino oligonucleotides (cMOs) or morpholinos targeting embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1)--binding sites in *tie1AS* (*tie1AS*-Elavl-bMO^comb^). They were then grown at 28.5°C in the dark and treated with 100 μm DMSO or 100 μm SB-505124 between somite stages 18 and 20. Around 28 hours post-fertilization (hpf), the embryos were imaged (**A**--**H**), and areas of eyes, ventricular space, and primordial midbrain channels (PMBCs) were quantified from 6 lateral images (**I**--**K**). Also, *tie1* mRNA levels in some embryos collected between 28 and 31 hpf were determined (**L**--**N**). **A**, A representative (156/180) phase-contrast image of a 28 hpf embryo injected with cMO and treated with DMSO (cMO+DMSO). **B**, A fluorescence image corresponding to **A**. **C**, A representative (165/216) phase-contrast image of a 28 hpf embryo injected with cMO and treated with SB-505124 (cMO+SB-505124). **D**, A fluorescence image corresponding to **C**. **E**, A representative (98/200) phase-contrast image of a 28 hpf embryo injected with *tie1AS*-Elavl-bMO^comb^ and treated with DMSO (*tie1AS*-Elavl-bMO^comb^+DMSO). **F**, A fluorescence image corresponding to **E**. **G**, A representative (152/200) phase-contrast image of a 28 hpf embryo injected with *tie1AS*-Elavl-bMO^comb^ and treated with SB-505124 (*tie1AS*-Elavl-bMO^comb^+SB-505124). **H**, A fluorescence image corresponding to **G**. White dotted lines outline PMBCs (also denoted by P). Outlines of eyes, ventricular spaces, and PMBCs were traced in lateral images (phase-contrast or fluorescence) with Axiovision 4.8.2, and areas within the outlines were deduced with the Measure tool from Axiovision 4.8.2. Average areas of eyes (**I**), ventricular spaces (**J**), and PMBCs (**K**) were deduced for the cMO+DMSO group (blue bars), the cMO+SB-505124 group (light gray bars), the *tie1AS*-Elavl-bMO^comb^+DMSO group (red bars), and the *tie1AS*-Elavl-bMO^comb^+SB-505124 group (dark grey bars). Error bars represent SDs (n=6). cMO+DMSO embryos (blue bars), cMO+SB-505124 embryos (light gray bars), *tie1AS*-Elavl-bMO^comb^+DMSO embryos (red bars), and *tie1AS*-Elavl-bMO^comb^+SB-505124 embryos (dark gray bars) were collected between 28 and 31 hpf. Their RNA was extracted from whole embryo (**L**), embryo head (**M**), and trunk/tail (**N**), and used in RT-qPCR. Average *tie1* mRNA levels (ratio to β-actin) were plotted in **L**, **M**. Error bars represent SDs. n=50 embryos or heads or trunks/tails per group, with a total of 3 biological replicates. Multi-group differences in **I**--**N** were analyzed using ANOVA followed by Tukey test. \*Adj (adjusted after multiple testing corrections) *P*\<0.5; \*\*Adj *P*\<0.01; and \*\*\*Adj *P*\<0.001. We found significant differences between the cMO+DMSO group vs the *tie1AS*-Elavl-bMO^comb^+DMSO group (black braces), the cMO+DMSO group vs the cMO+SB-505124 group (blue lines), the cMO+SB-505124 group vs the *tie1AS*-Elavl-bMO^comb^+DMSO group (gray lines), and the *tie1AS*-Elavl-bMO^comb^+DMSO group vs the *tie1AS*-Elavl-bMO^comb^+SB-505124 group (red lines).](atv-38-1562-g005){#F5}

To correlate phenotypic changes with *tie1* mRNA levels, we performed RT-qPCR on the groups outlined above. Compared with the cMO+DMSO group, the cMO+SB-505124 group showed the expected decrease (≈0.3-fold) in *tie1* mRNA levels across all tissues (whole embryo, head, trunk, and tail; Figure [5](#F5){ref-type="fig"}L through [5](#F5){ref-type="fig"}N, compare blue bars versus light gray bars). When we compared the cMO+DMSO group with the *tie1AS*-Elavl-bMO^comb^+DMSO group, we observed the same pattern of *tie1* mRNA levels as reported in Figure [3](#F3){ref-type="fig"} (Figure [5](#F5){ref-type="fig"}L through [5](#F5){ref-type="fig"}N, compare blue bars versus red bars). When we compared *tie1* mRNA levels in the *tie1AS*-Elavl-bMO^comb^+DMSO embryos with those in *tie1AS*-Elavl-bMO^comb^+SB-505124 embryos, we observed a decrease in *tie1* mRNA levels in whole embryo, head, tail, and trunk (Figure [5](#F5){ref-type="fig"}L through [5](#F5){ref-type="fig"}N, compare red bars versus dark gray bars). The cMO+DMSO group and the *tie1AS*-Elavl-bMO^comb^+SB-505124 group had comparable *tie1* mRNA levels across all tissues (Figure [5](#F5){ref-type="fig"}L through [5](#F5){ref-type="fig"}N, compare blue bars versus dark gray bars). Thus, administering SB-505124 to embryos that had been injected with *tie1AS*-Elavl-bMO^comb^ suppressed the increase in *tie1* mRNA levels reported in Figure [3](#F3){ref-type="fig"}.

In both cMO+SB-505124 and *tie1AS*-Elavl-bMO^comb^+SB-505124 groups, we noticed defects in trunk and tail vasculature, as reported previously.^[@R34]^ From our studies of drug treatment after cMO or *tie1AS*-Elavl-bMO^comb^ morpholino injections, we conclude that there is strong correlation between an increase in *tie1* mRNA levels, particularly in the head, and the occurrence of dilated PMBCs, reduced ventricular space, and smaller eye size.

Next, we counted endothelial cells in the dilated PMBCs in the CRISPRi/MO embryos. First, we injected MOs, pMOs, and CRISPRi into the transgenic embryos *Tg(kdrl: mCherry; NLS-EGFP*), which express mCherry in the vasculature and eGFP (enhanced green fluorescent protein) in endothelial cell nuclei. Then we counted endothelial cell nuclei in PMBCs. Compared with the embryos injected with cMO, those injected with *tie1AS*-Elavl-bMO^comb^ showed a 1.5-fold increase in the number of endothelial cells within the PMBCs (embryos with severe phenotypes were excluded from the analysis; Figure [6](#F6){ref-type="fig"}A through [6](#F6){ref-type="fig"}C). Similarly, the number of endothelial cells was higher in the *tie1AS*-Elavl-pMO embryos (Figure [6](#F6){ref-type="fig"}E and [6](#F6){ref-type="fig"}F) and the *tie1AS* knockdown embryos (Figure [6](#F6){ref-type="fig"}H and [6](#F6){ref-type="fig"}I) than in the control pMO embryos (Figure [6](#F6){ref-type="fig"}D and [6](#F6){ref-type="fig"}F) or the control knockdown embryos (Figure [6](#F6){ref-type="fig"}G and [6](#F6){ref-type="fig"}I). To further examine the correlation between increased *tie1* mRNA levels in the head and higher endothelial cell numbers within PMBCs, we counted endothelial cell numbers in embryos that were injected with *tie1AS*-Elavl-bMO^comb^ or cMO after being treated with SB-505124 or DMSO (treatments performed as in Figure [5](#F5){ref-type="fig"}). The *tie1AS*-Elavl-bMO^comb^+DMSO group showed the expected higher number (1.8-fold) of endothelial cells in PMBCs around 28 hpf compared with the cMO+DMSO embryos (Figure [6](#F6){ref-type="fig"}J versus 6L; and Figure [6](#F6){ref-type="fig"}L and [6](#F6){ref-type="fig"}N, compare blue bar versus red bar). The cMO+DMSO group and the cMO+SB-505124 group (Figure [6](#F6){ref-type="fig"}J versus 6K; Figure [6](#F6){ref-type="fig"}N, blue bar versus light gray bar) had similar numbers of endothelial cells along their PMBCs. However, the *tie1AS*-Elavl-bMO^comb^+SB-505124 embryos had only half as many endothelial cells along their PMBCs as the *tie1AS*-Elavl-bMO^comb^+DMSO (Figure [6](#F6){ref-type="fig"}L versus 6M; also, Figure [6](#F6){ref-type="fig"}N, compare red bar versus dark gray bar). Endothelial cell numbers along PMBCs in the *tie1AS*-Elavl-bMO^comb^+SB-505124 group and the cMO+DMSO/SB-505124 group were similar (Figure [6](#F6){ref-type="fig"}M versus 6J and 6K; also, Figure [6](#F6){ref-type="fig"}N, compare dark gray bar versus blue bar or light gray bar). Thus, suppressing the increase in *tie1* mRNA levels in the *tie1AS*-Elavl-bMO^comb^ embryos with SB-505124 rescued the endothelial cell number (within PMBCs) phenotype.

![Endothelial cell number in *Tg(kdrl:mCherry; NLS-eGFP* zebrafish embryos that expressed eGFP (enhanced green fluorescent protein) in endothelial cell nuclei and red fluorescent protein (mCherry) in blood vessels. A representative confocal image (z-stack) of a 28 hours post-fertilization (hpf) transgenic zebrafish embryo injected at the 1-cell stage with (**A**) Control morpholino oligonucleotide (cMO; 7 of 7 images), (**B**) *tie1AS*-Elavl-bMO^comb^ (8/10), (**C**) control pMO that was activated between somite stages14 and 16 by exposure to 365 nm ultraviolet light for 8 minutes (6/6), (**D**) *tie1AS*-Elavl-bMO:pMO mix (*tie1AS*-Elavl-pMO) that was photo-activated between 14 and 16 somite stages (6/6), (**E**) scrambled guide RNA (gRNA) and dCas9-KRAB (dead cas9 enzyme-kruppel-associated box domain; CRISPRi \[clustered regularly interspaced short palindromic repeats--mediated interference\] negative control; 6/6), (**F**) 3 gRNAs targeting transcription start site (TSS) of *tyrosine kinase containing immunoglobulin and epidermal growth factor homology 1 antisense* (*tie1AS*) along with dCas9-KRAB (*tie1AS* knockdown; 5/7). The average number of endothelial cells in the primordial midbrain channel (PMBC) of 28 hpf embryos injected with (**G**) Control morpholinos (cMO; blue diamond) or *tie1AS*-Elavl-bMO^comb^ (red diamond); (**H**) control photoactivatable MO (pMO; blue diamond) or *tie1AS*-Elavl-pMO (red diamond), which were photo-cleaved between somite stages 14 and 16. The other 2 groups were (**I**) the control knockdown (blue diamond) and the *tie1AS* knockdown (red diamond) embryos. The endothelial cells were counted manually on 6 merged z-stack images on Velocity 3D imaging software (Perkin Elmer). **J**--**M**, One-cell stage transgenic zebrafish embryos, *Tg(kdrl:mCherry; NLS-eGFP*, were injected with cMO or *tie1AS*-Elavl-bMO^comb^, grown at 28.5°C in the dark, and treated with 100 µm dimethyl sulfoxide (DMSO) or 100 µm SB-505124 between somite stages 18 and 20. Representative (6/6) confocal images (z-stack) of 28 hpf embryos are shown for (**J**) cMO+DMSO, (**I**) cMO+SB-505124, (**L**) *tie1AS*-Elavl-bMO^comb^+DMSO, and (**M**) *tie1AS*-Elavl-bMO^comb^+SB-505124. **N**, Average number of endothelial cells in cMO+DMSO embryos (blue bars), cMO+SB-505124 embryos (light gray bars), *tie1AS*-Elavl-bMO^comb^+DMSO embryos (red bars), and *tie1AS*-Elavl-bMO^comb^+SB-505124 embryos (dark gray bars). White rectangular boxes around PMBC in **A**--**F** and **J**--**M** denote regions where endothelial cell nuclei were counted. \*Adj *P*\<0.05 and \*\*adj *P*\<0.01 (*P* values were adjusted after multiple testing corrections). Error bars represent SDs (n=6). White horizontal bars at the **left bottom** corners of **A**--**F** and **J**--**M** are scale bars (50 µm).](atv-38-1562-g006){#F6}

In summary, increased *tie1* mRNA levels in the head between 28 and 31 hpf strongly correlated with dilated and distended PMBCs and with a higher number of endothelial cells in the PMBCs. Collectively, our data suggest that the *tie1AS*-Elavl1 complex plays an important role in regulating *tie1* mRNA levels in both space and time to achieve proper PMBC patterning in the developing zebrafish embryo.

Discussion
==========

These studies provide a mechanistic explanation for our previous observation that *tie1AS* mediates the degradation *tie1* mRNA.^[@R6]^ We show that binding of Elavl1 to a 10 nucleotide AU-rich element in *tie1AS* sustains *tie1AS* levels, facilitating the degradation of *tie1* mRNA in the cytoplasm. Blocking the interaction between Elavl1 and *tie1AS* with MOs and pMOs caused a ≈2-fold decrease in *tie1AS* levels in the head and a \>2-fold increase in *tie1* mRNA levels. CRISPRi confirmed this result, showing a 2.5-fold decrease in *tie1AS* in the head and a corresponding ≈2-fold increase in *tie1* mRNA levels. On the basis of these results, we hypothesize that Elavl1 plays an active role in the eventual degradation of *tie1* mRNA, using *tie1AS* as an intermediary. Our current model (Figure XX in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) is that the interaction of Elavl1 with *tie1AS* brings Elavl1 within proximity to the poly(A) tail of *tie1* mRNA, allowing Elavl1 to interfere with the interaction of poly(A) binding protein with *tie1* mRNA. This interaction also recruits proteins involved in the degradation of *tie1* mRNA. Indeed, Elav-like proteins have been shown to bind to AU-rich elements and poly(A) sequences simultaneously in vitro.^[@R35]^ Also, the Elavl1 binding site identified in zebrafish *tie1AS* is present in 1 of the 3 *TIE1AS* lncRNAs identified in humans^[@R6]^ and in mouse *Tie1AS* lncRNA (Figures XXI and XXII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Coincidently, the human *TIE1AS* variant that was previously shown to regulate *TIE1* mRNA and protein levels contains the Elavl1 binding site, and its position relative to the length of the lncRNA is also conserved (Figure XXI in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Thus, the mechanism proposed here could be evolutionarily conserved. This mechanism was implicated previously for an Elavl1 orthologue, HuR, which recruits proteins involved in the degradation of nucleophosmin mRNA.^[@R36]^

Coupling fluorescence in situ hybridization with immunofluorescence, we observed that *tie1* mRNA expression is restricted within head vessels (Figure [2](#F2){ref-type="fig"}A; Figure V in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), whereas *tie1AS* lncRNA (Figure [2](#F2){ref-type="fig"}B) and Elavl1 (Figure [2](#F2){ref-type="fig"}C) show broader expression in the head. In the 26 to 28 hpf head, we observed strong overlap in the expression of *tie1AS* lncRNA and Elav-like proteins in the forebrain, hindbrain, and eye (Figure IV in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Consistent with that expression pattern, interrupting the *tie1AS*-Elavl1 interaction (with MOs) restricted the abnormal phenotype primarily to the head (smaller eyes, dilated PMBCs, and reduced ventricular space), and few or no changes were observed in the trunk (26--28 hpf), where no overlap between *tie1AS* lncRNA and Elav-like proteins was evident (Figure III in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). Thus, we hypothesize that the head phenotype (smaller eyes, dilated PMBCs, and reduced ventricular space) associates with the interaction between *tie1AS* and Elavl1. In addition, when we used CRISPRi to knock down *tie1AS*, we observed trunk intersomitic vessel defects in ≈35% of the embryos (data not shown). In this approach, we downregulated *tie1AS* levels without influencing the interaction between *tie1AS* and Elavl1. Thus, the intersomitic vessel defects observed in the CRISPRi embryos likely associate with *tie1AS* via an Elavl1-independent mechanism. Another possibility that cannot be excluded is that *tie1AS* may possess additional functions (other than regulating *tie1* mRNA) that influence intersomitic vessel development. These questions need further evaluation.

From a vascular phenotype perspective, the PMBCs in the head are influenced by modulating the *tie1AS*-Elavl1 interaction. During vasculogenesis, PMBCs give rise to all the superficial zebrafish ocular vessels.^[@R37]^ Expression of *tie1*, *tie1AS*, and Elavl1 in PMBCs at 26 to 28 hpf indicates some overlap between Elavl1 and *tie1* (Figure VIIB in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) but no overlap between Elavl1 and *tie1AS* (Figure VIIA in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)) or between *tie1* and *tie1AS* (Figure VIIC in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)). The overlap observed between Elavl1 and *tie1* in fluorescence in situ hybridization and immunofluorescence does not necessarily imply interaction because in vivo pull-down assays showed no interaction between *tie1* mRNA and Elavl1 (Figure [1](#F1){ref-type="fig"}D).

If the colocalization of *tie1AS* and Elavl1 in PMBCs is minimal at 26 to 28 hpf, how can we understand the PMBC dilation phenotype? Our spatial expression analysis of *tie1*, *tie1AS*, and Elavl1 provides an explanation. We hypothesize that the interaction between *tie1AS and* Elavl1 occurs in cells surrounding PMBCs, preventing those cells from expressing *tie1*. Thus, the interaction creates *tie1*-negative boundaries in the head at 26 to 28 hpf. If functional approaches are used to influence the *tie1AS*-Elavl1 interaction or decrease *tie1AS* levels (CRISPRi), *tie1* mRNA levels increase abruptly in cells originally destined for *tie1*-negative status. Support for this idea emerged from our expression analysis involving chromogenic in situ hybridization, in which PMBCs in embryos injected with *tie1AS*-Elavl-bMO^comb^ showed spatial expansion of *tie1* mRNA expression (Figure [4](#F4){ref-type="fig"}M versus 4N; Figure XII in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)).

Indeed, increased *tie1* mRNA levels are linked to PMBC dilation, as shown by our small molecule approach. SB-505124, a small molecule that selectively inhibits activin receptor-like kinases, was previously shown to decrease *tie1* mRNA expression in zebrafish.^[@R34]^ When we injected embryos with cMO or *tie1AS*-Elavl-bMO^comb^ and treated them with DMSO, vehicle control, or SB-505124, we observed the expected decrease in *tie1* mRNA in the heads of the cMO+SB-505124 embryos (Figure [5](#F5){ref-type="fig"}L through [5](#F5){ref-type="fig"}N). The *tie1AS*-Elavl-bMO^comb^+DMSO embryos showed the expected increase in *tie1* mRNA in the head, which was brought down to control levels by SB-505124 treatment (Figure [5](#F5){ref-type="fig"}L and [5](#F5){ref-type="fig"}M). Importantly, the eye size, ventricular space, and PMBC dilation phenotypes were all rescued when the *tie1AS*-Elavl-bMO^comb^ embryos were treated with SB-505124 (Figure [5](#F5){ref-type="fig"}I through [5](#F5){ref-type="fig"}K). SB-505124 treatment of embryos injected with cMO or *tie1AS*-Elavl-bMO^comb^ upregulated *tie1AS* expression in the head and trunk/tail (Figure XIX in the [online-only Data Supplement](http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310848/-/DC1)), which was unexpected but does coincide with the reduction in *tie1* mRNA levels and defects in the trunk and tail. We hypothesize that defects in the trunk and tail could arise from either suboptimal levels of *tie1* mRNA that are independent of *tie1AS* or are caused by an Elavl1-independent mechanism of *tie1AS* or by many genes, including *tie1*, that are affected by SB-505124.

In conclusion, our findings show that vascular patterning in the brain associated with *tie1* is fine-tuned by a low-abundance transcript, *tie1AS*, which interacts with an abundant RNA-binding protein, Elavl1, in a temporal and spatial manner. Thus, regulation of *tie1* mRNA mediated by the *tie1AS*:Elavl1 complex is critical during development.
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Highlights
==========

-   *Tie1 antisense* (*tie1AS*) long noncoding RNA binds embryonic lethal and abnormal vision Drosophila-like 1 (Elavl1) in vitro and in vivo.

-   The interaction between *tie1AS* and Elavl1 fine-tunes tissue-specific *tie1* mRNA expression.

-   An increase in *tie1* mRNA levels because of perturbation of *tie1AS*-mediated regulation of *tie1* mRNA coincides with reduced ventricular space, smaller eye size, and dilated primordial midbrain channels.
